Race ramps up between Pfizer and Moderna

18 November 2020
| By Laura Dew |
image
image
expand image

As the race ramps up between the two companies to successfully create a COVID-19 vaccine, one firm has vastly outpaced the other with share price rise of 409% since the start of the year.

It was announced this week that US drug firm Moderna had created a vaccine with 94% effectiveness while Pfizer had a successful trial, in partnership with German biotech firm BioNTech, with 90% effectiveness earlier this month. 

Moderna’s shares rose 12% on the news, compared to 15% for Pfizer and 23% for BioNTech after their joint announcement, but shares in the US firm had risen much more sharply over the past year.

The firm was far younger than Pfizer having been set up in Massachusetts a decade ago and only listing on the NASDAQ in December 2018. Since listing, shares had returned 424%.

Shares had risen 409% since the start of the year as the company announced its plans to work on a vaccine before it later announced a successful trial in November.

According to FE Analytics, there were no funds within the Australian Core Strategies universe which were holding Moderna. There were three holding Pfizer and two holding BioNTech, these were Platinum European and Platinum International Health Care holding the European biotech firm and BetaShares Global Healthcare ETF, CFS FirstChoice Acadian Wholesale Geared Global Equity and Dimensional Global Value Trust holding the US pharma major.

Seema Shah, chief strategist at Principal Global Investors, said: “The global population couldn’t have asked for more from the Moderna vaccine. With an almost 95% efficacy and more acceptable logistical and storage dynamics, [Moderna’s] news should solidify the market rally that has been in play since last week. Visibility towards a return to normality is increasing, and this should provide more fuel to the reflation rally, with small caps, value and cyclicals clear beneficiaries.”

Janus Henderson portfolio manager, Andy Acker, and director of research, Matt Peron, said: “The news from Pfizer and BioNTech raises hope that a solution may be on the horizon and other vaccines targeting the same SARS CoV-2 protein – including a second mRNA therapy from Moderna – may be successful.

“The approval of multiple vaccines is viewed as critical to quickly and effectively protecting the world’s population with important implications for the global economy. What’s more, mRNA platforms could be readily modified to address new versions of the virus in the future, should that become necessary.”

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

GG

So shareholders lose a dividend plus have seen the erosion of value. Qantas decides to clawback remuneration from Alan ...

2 months 1 week ago
Denise Baker

This is why I left my last position. There was no interest in giving the client quality time, it was all about bumping ...

2 months 1 week ago
gonski

So the Hayne Royal Commission has left us with this. What a sad day for the financial planning industry. Clearly most ...

2 months 1 week ago

A Sydney-based financial adviser has been banned from providing financial services in the interest of consumer protection after failing to act on conduct concerns. ...

3 weeks 3 days ago

ASIC has cancelled the AFSL of a $250 million Sydney fund manager, one of two AFSL cancellations announced by the corporate regulator....

3 weeks 1 day ago

Having divested its advice business in August, AMP is undergoing restructuring in at least four other departments amid a cost simplification program....

2 weeks 5 days ago